

# ACTA MEDICINAE 1/2012 KARDIOLOGIE

## Kompletní literatura

- 2 **Současné postavení amlodipinu v léčbě systémové hypertenze**  
MUDr. Petr Lepší Klinika JL, kardiologická ambulance, Praha
- 2 **Renální denervace – nové možnosti nejen u nemocných s rezistentní hypertenzí**  
doc. MUDr. Petr Neužil, CSc., FESC Kardiologické oddělení Nemocnice Na Homolce, Praha  
MUDr. Zdeněk Stárek I. interní klinika Fakultní nemocnice u sv. Anny, Brno
- 2 **Lékové stenty – jejich indikace, problém akutní a odložené trombózy**  
MUDr. Ondřej Aschermann | doc. MUDr. Martin Mates, CSc. | MUDr. Pavel Formánek  
Kardiologické oddělení Nemocnice Na Homolce, Praha
- 4 **Kombinační léčba hypertenze**  
doc. MUDr. Jiří Špác, CSc. 2. interní klinika Fakultní nemocnice u sv. Anny, Brno
- 5 **Nové principy antitrombotické terapie u nemocných s fibrilací síní**  
MUDr. Jana Matoušková | doc. MUDr. Petr Neužil, CSc., FESC  
Kardiologické oddělení Nemocnice Na Homolce, Praha
- 5 **Nová farmaka v terapii fibrilace síní**  
MUDr. Lucie Šedivá, Ph.D.  
Antiarytmická jednotka, Kardiologické oddělení Nemocnice na Homolce, Praha
- 6 **Katetrizační ablace fibrilace síní: indikace, metody, výsledky**  
MUDr. Jan Petruš Antiarytmická jednotka, Kardiologické oddělení Nemocnice Na Homolce, Praha
- 6 **Natriuretické peptidy a nové biomarkery chronického srdečního selhání**  
doc. MUDr. Filip Málek, Ph.D., MBA  
Ambulance srdečního selhání, Kardiologické oddělení Nemocnice Na Homolce, Praha
- 8 **Srdeční amyloidóza – od historie k moderní diagnostice**  
doc. MUDr. Eva Mandysová, CSc. | doc. MUDr. Petr Neužil, CSc., FESC  
Kardiologické oddělení Nemocnice na Homolce, Praha
- 8 **Očkování proti pertusi**  
MUDr. Kateřina Fabiánová Státní zdravotní ústav,  
Centrum epidemiologie a mikrobiologie, Oddělení epidemiologie infekčních nemocí,  
3. lékařská fakulta Univerzity Karlovy, Ústav epidemiologie
- 9 **Pohled ambulantního lékaře na očkování proti HPV**  
MUDr. Jiří Dvořák člen HPV College, Gynekologická ambulance, Kolín
- 9 **Inkretiny a jejich místo v terapii diabetu**  
MUDr. Mgr. Sylvie Špitálníková, Ph.D. | MUDr. Jiří Hradec Diabetologická ambulance, Chrudim
- 10 **Imunologické a epidemiologické aspekty pneumokokového očkování**  
RNDr. Marek Petráš InterImun, s. r. o., Pardubice
- 10 **Najde přenos buněčných jader uplatnění v medicíně?**  
prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

# Současné postavení amlodipinu v léčbě systémové hypertenze

MUDr. Petr Lepší Klinika JL, kardiologická ambulance, Praha

- 1 **Suchopár, J. – Bultas, J.:** Fixní kombinace telmisartanu a amlodipinu. *Remedia*, 2011, 21, s. 126–138.
- 2 **Málek, F.:** Fixní kombinace inhibitorů angiotensin-konvertujícího enzymu v praxi. *Interní medicína pro praxi*, 2010, 12 (9), s. 424–426.
- 3 **Dong-ChurlSuh – Chul-Min-Kim – In-Sun-choi – Craig, A. – Plauschnat, J. – Barone, A.:** Trendy kompenzace a léčby krevního tlaku u pacientů s diabetes mellitus 2. typu a hypertenzí ve Spojených státech: 1988–2004. *Journal of Hypertension*, české vydání 2010, 1 (1), s. 3–11.
- 4 **Málek, F.:** Novinky z kongresu Evropské společnosti pro hypertenzi: 21<sup>st</sup> European Meeting of Hypertension and Cardiovascular Prevention (ESH). *Medicína pro praxi*, 2011, 8 (9), s. 394–397.
- 5 **Bertrand, M. E.:** Kombinace perindopril/amlodipin: optimální synergie při ochraně kardiovaskulárního systému. *European Heart Journal Supplements*, 2009, 11 (dopl. E), s. E22–E25, doi: 10, 1093/eurheartj/sup019.
- 6 **Widimský, J.:** Kombinační léčba hypertenze. Seminární sborník *Současný pohled na pacienta se zvýšeným KV rizikem*. Infofarm, s. 12–19.
- 7 **Suchopár, J.:** Lékové interakce antihypertenziv s jinými léčivými. Seminární sborník *Současný pohled na pacienta se zvýšeným KV rizikem*. Infofarm, s. 22–23.

## Renální denervace – nové možnosti nejen u nemocných s rezistentní hypertenzí

doc. MUDr. Petr Neužil, CSc., FESC Kardiologické oddělení Nemocnice Na Homolce, Praha

MUDr. Zdeněk Stárek I. interní klinika Fakultní nemocnice u sv. Anny, Brno

- 1 **Kearney, P. M. – Whelton, M. – Reynolds, K. – Muntner, P. – Whelton P. K. – He, J.:** Global burden of hypertension: analysis of worldwide data. *Lancet*, 2005, 365, s. 217–223.
- 2 **Sarafidis, P. A. – Bakris, G. L.:** Resistant hypertension: an overview of evaluation and treatment. *J Am Coll Cardiol*, 2008, 52, s. 1749–1757.
- 3 **Cutler, J. A. – Sorlie, P. D. – Wolf, M. – Tom, T. – Fields, L. E. – Roccella, E. J.:** Trends in hypertension prevalence, awareness, treatment and control rates in United States adults between 1988–1994 and 1999–2004. *Hypertension*, 2008, 52, s. 818–827.
- 4 **Calhoun, D. A. – Jones, D. – Textor, S., et al.:** Resistant hypertension: diagnosis, evaluation and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure. *Circulation Research*, 2008, 117, s. 510–526.
- 5 **Morrissey, D. M. – Brookes, V. S. – Cooke, W. T.:** Sympathectomy in the treatment of hypertension; review of 122 cases. *Lancet*, 1953, 1, s. 403–408.
- 6 **Smithwick, R. H. – Thompson, J. E.:** Splanchnicectomy for essential hypertension: results in 1,266 cases. *J Am Med Assoc*, 1953, 152, s. 1501–1504.
- 7 **Krum, H. – Schaich, M. – Whitbourn, R. – Sobotka, P. A. – Sadowski, J. – Bartus, K., et al.:** Catheter – based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. *Lancet*, 2009, 373, s. 1275–1281.
- 8 **Esler, M. D. – Krum, H. – Sobotka, P. A. – Schlaich, M. P. – Schmieder, R. E. – Böhm, M.:** Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. *Lancet*, 2010, 376, s. 1903–1909.
- 9 **van Jaarsveld, B. C. – Krijnen, P. – Pieterman, H. – et al.:** The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. *N Engl J Med*, 2000, 342 (14), s. 1007–1014.

## Lékové stenty – jejich indikace, problém akutní a odložené trombózy

MUDr. Ondřej Aschermann | doc. MUDr. Martin Mates, CSc. | MUDr. Pavel Formánek

Kardiologické oddělení Nemocnice Na Homolce, Praha

- 1 **Morice, M. C. – Serruys, P. W. – Sousa, J. E., et al.:** For the RAVEL Study Group: A randomized comparison of sirolimus eluting stent with a standard stent for coronary revascularization. *N Engl J Med*, 2002, 346, s. 1773–1780.
- 2 **Moses, J. – Leon, M. B. – Popma, J. J., et al.:** For SIRIUS Investigators: Sirolimus eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N Engl J Med*, 2003, 349, s. 1315–1323.
- 3 **Stone, G. W. – Rizvi, A. – Newman, W. – Mastali, K. – Wang, J. C. – Caputo, R. – Doostzadeh, J. – Cao, S. – Simonton, C. A. – Sudhir, K. – Lansky, A. J. – Cutlip, D. E. – Kereiakes, D. J.:** Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. *N Engl J Med*, 2010, 362, s. 1663–1674.
- 4 **Wijns, W., et al.:** Guidelines on myocardial revascularization. *European Heart Journal*, doi:10.1093/eurheartj/ehq277.
- 5 **Cypher sirolimus eluting coronary stent on Raptor over-the-wire delivery system -P020026:** proval order. Rockville, MD, Food and Drug Administration, 2003.
- 6 **Taxus Express2 paclitaxel-eluting coronary stent system (monorail and over-the-wire) P030025:** proval order. Rockville, MD, Food and Drug Administration, 2003.

- 7 Daemen, J. – Wenaweser, P. – Tsuchida, K. – Abrecht, L. – Vaina, S. – Morger, C. – Kukreja, N. – Juni, P. – Sianos, G. – Hellige, G. – van Domburg, R. T. – Hess, O. M. – Boersma, E. – Meier, B. – Windecker, S. – Serruys, P. W.: Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. *Lancet*, 2007, 369, s. 667–678.
- 8 Iakovou, I. – Schmidt, T. – Bonizzoni, E. – Ge, L. – Sangiorgi, G. M. – Stankovic, G. – Airoldi, F. – Chieffo, A. – Montorfano, M. – Carlino, M. – Michev, I. – Corvaja, N. – Briguori, C. – Gerckens, U. – Grube, E. – Colombo, A.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. *JAMA*, 2005, 293, s. 2126–2130.
- 9 Kuchulakanti, P. K. – Chu, W. W. – Torguson, R. – Ohlmann, P. – Rha, S. W. – Clavijo, L. C. – Kim, S. W. – Bui, A. – Gevorkian, N. – Xue, Z. – Smith, K. – Fournadjieva, J. – Suddath, W. O. – Satler, L. F. – Pichard, A. D. – Kent, K. M. – Waksman, R.: Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. *Circulation*, 2006, 113, s. 1108–1113.
- 10 Piccolo, R. – Cassese, S. – Galasso, G. – De Rosa, R. – D’Anna, C. – Piscione, F.: Long-term safety and efficacy of drug-eluting stents inpatients with acute myocardial infarction: A meta-analysis of randomized trials. *Atherosclerosis*, 2011, 217, s. 149–157.
- 11 Dibra, A. – Tiroch, K. – Schulz, S. – Kelbæk, H. – Spaulding, C. – Laarman, G. J. – Valgimigli, M. – Di Lorenzo, E. – Kaiser, C. – Tierala, I. – Mehilli, J. – Campo, G. – Thuesen, L. – Vink, M. A. – Schlij, M. J. – Violini, R. – Schömig, A. – Kastrati, A.: Drug-eluting stents in myocardial infarction: updated meta-analysis of randomized trials. *Clin Res Cardiol*, 2012, 99, s. 345–357.
- 12 Spaulding, C. H., et al.: Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction treated with Angioplasty (TYPHOON). ACC Annual Scientific Session, Atlanta, března 2006.
- 13 Dirksen, M. T., et al.: Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION). ACC Annual Scientific Session, Atlanta, března 2006.
- 14 Menichelli, M., et al.: Sirolimus Stent vs Bare Stent in Acute Myocardial Infarction (SESAMI trial). EuroPCR, Paříž, květen 2006.
- 15 Tebaldi, M. – Arcozzi, C. – Campo, G. – Percoco, G. – Ferrari, R. – Valgimigli, M.: The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction. *J Am Coll Cardiol*, 2009, 54, s. 1900–1901.
- 16 Vink, M. A. – Dirksen, M. T. – Suttrop, M. J. – Tijssen, J. G. – Patterson, M. S. – Slagboom, T. – Kiemeneij, F. – Laarman, G. J.: 5-Year Follow-Up After Primary Percutaneous Coronary Intervention With a Paclitaxel-Eluting Stent Versus a Bare-Metal Stent in Acute ST-Segment Elevation Myocardial Infarction A Follow-Up Study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction With ST-Segment Elevation) Trial. *JACC Cardiovasc Interv*, 2011, 4, s. 24–29.
- 17 Boden, H. – van der Hoeven, L. – Liem, S. – Atary, J. Z. – Cannegieter, S. C. – Atsma, D. E. – Bootsma, M. – Jukema, J. W. – Zeppenfeld, K. – Oemrawsingh, P. V. – van der Wall, E. E. – Schlij, M. J.: *EuroIntervention*, 2012, 7, s. 1021–1029.
- 18 Lagerqvist, B. – James, S. K. – Stenström, U. – Lindback, J. – Nilsson, T. – Wallentin, L.: Long-term outcomes with drug-eluting stents versus baremetal stents in Sweden. *N Engl J Med*, 2007, 356, s. 1009–1019.
- 19 Nordmann, A. J. – Briel, M. – Bucher, H. C.: Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis. *Eur Heart J*, 2006, 27, s. 2784–2814.
- 20 Vermeersch, P. – Agostoni, P. – Verheye, S. – Van den Heuvel, P. – Convens, C. – Van den Branden, F. – Van Langenhove, G.: DELAYED RRISC Investigators. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. *J Am Coll Cardiol*, 2007, 50, s. 261–267.
- 21 Brilakis, E. S. – Lichtenwalter, C. – de Lemos, J. A. – Roesle, M. – Obel, O. – Haagen, D. – Saeed, B. – Gadiparthi, C. – Bissett, J. K. – Sachdeva, R. – Voudris, V. V. – Karyofillis, P. – Kar, B. – Rossen, J. – Fasseas, P. – Berger, P. – Banerjee, S.: A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. *J Am Coll Cardiol*, 2009, 53, s. 919–928.
- 22 Gioia, G. – Benassi, A. – Mohendra, R. – Chowdhury, K. – Masood, I. – Matthai, W.: Lack of clinical long-term benefit with the use of a DES compared to use of a bare metal stent in saphenous vein grafts. *Catheter Cardiovasc Interv*, 2008, 72, s. 13–20.
- 23 Lee, M. S. – Shah, A. P. – Aragon, J. – Jamali, A. – Dohad, S. – Kar, S. – Makkar, R. R.: Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. *Catheter Cardiovasc Interv*, 2005, 66, s. 507–511.
- 24 Okabe, T. – Lindsay, J. – Buch, A. N. – Steinberg, D. H. – Roy, P. – Slotow, T. L. – Smith, K. – Torguson, R. – Xue, Z. – Satler, L. F. – Pichard, A. D. – Weissman, N. J. – Waksman, R.: Drug-eluting stents versus bare metal stents for narrowing in saphenous vein grafts. *Am J Cardiol*, 2008, 102, s. 530–534.
- 25 Ramana, R. K. – Ronan, A. – Cohoon, K. – Homan, D. – Sutherland, J. – Steen, L. – Liu, J. – Loeb, H. – Lewis, B. E.: Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease. *Catheter Cardiovasc Interv*, 2008, 71, s. 886–893.
- 26 Vignali, L. – Saia, F. – Manari, A. – Santarelli, A. – Rubboli, A. – Varani, E. – Piovaccari, G. – Menozzi, A. – Percoco, G. – Benassi, A. – Rusticali, G. – Marzaroli, P. – Guastaroba, P. – Grilli, R. – Maresta, A. – Marzocchi, A.: Long-term outcomes with drug-eluting stents versus bare metal stents in the treatment of saphenous vein graft disease (results from the REgistro RegionalengiopLastiche Emilia-Romagna registry). *Am J Cardiol*, 2008, 101, s. 947–952.
- 27 Daemen, J. – Kuck, K. H. – Macaya, C. – LeGrand, V. – Vrolix, M. – Carrie, D. – Sheiban, I. – Suttrop, M. J. – Vranckx, P. – Rademaker, T., et al.: Multivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. *J Am Coll Cardiol*, 2008, 52, s. 1957–1967.
- 28 Hlatky, M. A. – Boothroyd, D. B. – Bravata, D. M. – Boersma, E. – Booth, J. – Brooks, M. M. – Carrie, D. – Clayton, T. C. – Danchin, N. – Flather, M., et al.: Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet*, 2009, 373, s. 1190–1197.
- 29 Stettler, C. – Wandel, S. – Allemann, S. – Kastrati, A. – Morice, M. C. – Schomig, A. – Pfisterer, M. E. – Stone, G. W. – Leon, M. B. – de Lezo, J. S., et al.: Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. *Lancet*, 2007, 370, s. 937–948.
- 30 Kastrati, A. – Mehilli, J. – Pache, J. – Kaiser, C. – Valgimigli, M. – Kelbæk, H. – Menichelli, M. – Sabate, M. – Suttrop, M. J. – Baumgart, D., et al.: Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. *N Engl J Med*, 2007, 356, s. 1030–1039.
- 31 Aaron, M. – Firas, J. – Al Badarin – Stephen, S. – Charanjit, Ch. – Rihal, S.: Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis of data from the ARTS II, CARDia, ERACI III, and SYNTAX studies and systematic review of observational data *EuroIntervention*, 2010, 6, s. 269–276.
- 32 Baker, J.: Multivessel Heart Disease. *DukeMed*, 10, 2008.
- 33 Kamallesh, M.: www.clinicaltrials.gov registration number NCT00326196 Coronary Artery Revascularization in Diabetes (VA CARDS).
- 34 Fuster, V.: Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes (FREEDOM). www.clinicaltrials.gov, registration number NCT00086450.

- 35 Schuler, G. – Mohr, F.: Percutaneous Coronary Intervention (PCI) With Drug-Eluting Stents (DES) Versus Coronary Artery Bypass Graft (CABG) for Patients With Significant Left Main Stenosis. www.clinicaltrials.gov, registration number NCT00176397.
- 36 Brener, S. J. – Lytle, B. W. – Casserly, I. P. – Schneider, J. P. – Topol, E. J. – Lauer, M. S.: Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. *Circulation*, 2004, 109, s. 2290–2295.
- 37 Hannan, E. L. – Racz, M. J. – Walford, G. – Jones, R. H. – Ryan, T. J. – Bennett, E. – Culliford, A. T. – Isom, O. W. – Gold, J. P. – Rose, E. A.: Long-term outcomes of coronary-artery bypass grafting versus stent implantation. *N Engl J Med*, 2005, 352, s. 2174–2183.
- 38 Hannan, E. L. – Wu, C. – Walford, G. – Culliford, A. T. – Gold, J. P. – Smith, C. R. – Higgins, R. S. – Carlson, R. E. – Jones, R. H.: Drug-eluting stents vs. coronary-artery bypass grafting in multivessel coronary disease. *N Engl J Med*, 2008, 358, s. 331–341.
- 39 Malenka, D. J. – Leavitt, B. J. – Hearne, M. J. – Robb, J. F. – Baribeau, Y. R. – Ryan, T. J. – Helm, R. E. – Kellett, M. A. – Dauerman, H. L. – Dacey, L. J. – Silver, M. T. – VerLee, P. N. – Weldner, P. W. – Hettelman, B. D. – Olmstead, E. M. – Piper, W. D. – O'Connor, G. T.: Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. *Circulation*, 2005, 112, s. 1371–1376.
- 40 Smith, P. K. – Califf, R. M. – Tuttle, R. H. – Shaw, L. K. – Lee, K. L. – DeLong, E. R. – Lilly, R. E. – Sketch, M. H. Jr. – Peterson, E. D. – Jones, R. H.: Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. *Ann Thorac Surg*, 2006, 82, s. 1420–1428.
- 41 Dzavik, V. – Ghali, W. A. – Norris, C. – Mitchell, L. B. – Koshal, A. – Saunders, L. D. – Galbraith, P. D. – Hui, W. – Faris, P. – Knudtson, M. L.: Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. *Am Heart J*, 2001, 142, s. 119–126.
- 42 Basel Stent Cost-effectiveness Trial-Late Thrombotic Events (BASKET-LATE) BASKETLATE. ACC Annual Scientific Scession 2006, Atlanta.
- 43 Cook, S. – Ladich, E. – Nakazawa, G. – Eshtehardi, P. – Neidhart, M. – Vogel, R. – Togni, M. – Wenaweser, P. – Billinger, M. – Seiler, C. – Gay, S. – Meier, B. – Pichler, W. J. – Juni, P. – Virmani, R. – Windecker, S.: Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. *Circulation*, 2009, 120, s. 391–399.
- 44 Stefanini, G. G. – Kalesan, B. – Serruys, P. W. – Heg, D. – Buszman, P. – Linke, A. – Ischinger, T. – Klauss, V. – Eberli, F. – Wijns, W. – Morice, M. C. – Di Mario, C. – Corti, R. – Antoni, D. – Sohn, H. Y. – Eerdmans, P. – van Es, G. A. – Meier, B. – Windecker, S. – Jüni, P.: Long-term clinical outcomes of bio-degradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. *Lancet*, 2011, 3, 378, s. 1940–1948.
- 45 Navarese, E. P. – Kubica, J. – Castriota, F. – Gibson, C. M. – De Luca, G. – Buffon, A. – Bolognese, L. – Margheri, M. – Andreotti, F. – Di Mario, C. – De Servi, S.: Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. *EuroIntervention*, 2011, 7, s. 985–994.
- 46 Daemen, J. – Wenaweser, P. – Tsuchida, K. – Abrecht, L. – Vaina, S. – Morger, C. – Kukreja, N. – Juni, P. – Sianos, G. – Hellige, G. – van Domburg, R. T. – Hess, O. M. – Boersma, E. – Meier, B. – Windecker, S. – Serruys, P. W.: Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. *Lancet*, 2007, 369, s. 667–678.
- 47 Gershlick, A. – Kandzari, D. E. – Leon, M. B. – Wijns, W. – Meredith, I. T. – Fajadet, J. – Popma, J. J. – Fitzgerald, P. J. – Kuntz, R. E.: Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. *Am J Cardiol*, 2007, 100, s. 45M–55M.
- 48 Patti, G. – Colonna, G. – Pasceri, V., et al.: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. *Circulation*, 2005, 111, s. 2099–2106.
- 49 Wenaweser, P. – Doffler-Melly, J. – Imboden, K., et al.: Stent Thrombosis Is Associated With an Impaired Response to Antiplatelet Therapy. *J Am Coll Cardiol*, 2005, 45, s. 1748–1752.

## Kombinační léčba hypertenze

doc. MUDr. Jiří Špác, CSc. 2. interní klinika Fakultní nemocnice u sv. Anny, Brno

- 1 Kannel, W. B.: Risk stratification in hypertension: new insights from the Framingham Study. *Am J Hypertens*, 2000, 13, s. 3S–10S.
- 2 Pitt, B. – Byington, R. P. – Furberg, C. D. – Hunninghake, D. B. – Mancini, J. – Miller, M. E. – Riley, W.: PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. *Circulation*, 2000, 102, s. 1503–1510.
- 3 The CAFE Investigators: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes. Principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation*, 2006, 113, s. 1213–1225.
- 4 Williams, B. – Lacy, P. S. – Thom, S. M., for the CAFE and ASCOT Investigators: Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation study: the CAFE Study. *Circulation*, 2006, 113, s. 1213–1225.
- 5 Sever, P. S. – Dahlof, B. – Poulter, N. R., et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*, 2003, 361, s. 1149–1158.
- 6 Sever, P. – Dahlof, B. – Poulter, N. – Wedel, H. – Beevers, G. – Caulfield, M., et al.: Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. *Eur Heart J*, 2006, 27, s. 2982–2988.
- 7 Messerli, F. H. – Pinto, L. – Tang, S. S. K., et al.: Impact of systemic hypertension on the cardiovascular benefits of statin therapy – a meta-analysis. *Am J Cardiol*, 2008, 101, s. 319–325.
- 8 Preiss, D. – Seshasai, S. R. – Welsh, P., et al.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. *JAMA*, 2011, 305, s. 2556–2564.
- 9 Reiner, Ž – Catapano, A. L. – De Backer, G., et al.: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS): ESC/EAS Guidelines for the management of dyslipidaemias. *European Heart Journal*, 2011, 32, s. 1769–1818.

# Nové principy antitrombotické terapie u nemocných s fibrilací síní

MUDr. Jana Matoušková | doc. MUDr. Petr Neužil, CSc., FESC

Kardiologické oddělení Nemocnice Na Homolce, Praha

- 1 Schirmer, S. H. – Baumhakel, M. – Neuberger, H. R., et al.: Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation. *Journal of the American College of Cardiology*, 2010, 25, s. 2067–2076.
- 2 Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S. – Phil, D., et al.: Dabigatran versus Warfarin in Patients with Atrial Fibrillation. *N. Engl J Med*, 2009, 361, s. 1–13.
- 3 Fabregas, J. M. – Mateo, J.: Old and New Anticoagulant Agents for the Prevention and Treatment of Patients with Ischemic Stroke. *Cerebrovasc. Dis.*, 2009, 27 (dopl. 1), s. 111–119.
- 4 Garnock-Jones, K. P.: Dabigatran Etexililate. *Am.J.Cardiovasc. Drugs*, 2011, 11, s. 57–72.
- 5 Ryn, J. – Stangier, J. – Haertter, S., et al.: Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. *Thrombosis and Haemostasis*, 2010, 103, s. 1116–1127.
- 6 Cairns, J. A. – Connolly, S. – McMurry, S., et al.: Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Prevention of Stroke and Systemic Thromboembolism in Atrial Fibrillation and Flutter. *Canadian Journal of Cardiology*, 2011, 27, s. 74–90.
- 7 Kvasnička, J. – Sliva, J.: Dabigatran. *Farmakoterapie*, 2008, 4, s. 359–364.
- 8 Lindahl, T. L. – Baghaei, F. – Blixter, I. F., et al.: Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. *Thrombosis and Haemostasis*, 2011, 105, s. 371–378.
- 9 Oldgren, J. – Budaj, A. – Granger, C. B., et al.: Randomised Dabigatran Etexililate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin And Clopidogrel (RE-DEEM). *American Heart Association. The Online Abstract Submission System*, 2009.
- 10 Walentin, L. – Yusuf, S. – Ezekowitz, M. D., et al.: Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet*, 2010, 376, s. 975–983.
- 11 Pradax Product Monograph. Dabigatran Etexililate Capsules 75 mg, 110 mg a 150 mg. Boehringer Ingelheim Canada, Ltd., 2010.
- 12 SPC přípravku Pradaxa 110 a 150 mg. SUKL Praha, 2011.

## Nová farmaka v terapii fibrilace síní

MUDr. Lucie Šedivá, Ph.D.

Antiarytmická jednotka, Kardiologické oddělení Nemocnice na Homolce, Praha

- 1 Wijffels, M. C. – Kirchhof, C. J. – Dorland, R., et al.: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation*, 1995, 92, s. 1954–1968.
- 2 Waldo, A. L.: A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: There remains an unmet need. *Am Heart J*, 2006, 151, s. 771–778.
- 3 Vassallo, P. – Trohman, R. G.: Prescribing amiodarone: an evidence-based review of clinical Indications. *JAMA*, 2007, 298, s. 1312–1322.
- 4 Conway, E. – Musco, S. – Kowey, P. R.: New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? *Am J Cardiol*, 2008, 102 (dopl.), s. 12H–19H.
- 5 Votava, M. – Doležal, T.: Ibutilid. *Remedia*, 2000, 12, s. 164–165.
- 6 Walker, D. K. – Alabaster, C. T. – Congrave, G. S. – Hargreaves, M. B. – Hyland, R. – Jones, B. C., et al.: Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. *Drug Metab Dispos*, 1996, 24, s. 447–455.
- 7 Dofetilide investigators: Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Danish Investigation of Arrhythmia and Mortality on Dofetilide. *Clin Cardiol*, 1997, 20, s. 704–710.
- 8 Waldo, A. L. – Camm, A. J. – de Ruyter, H. – Friedman, P. I. – Mac Neil, D. J. – Pauls, J. F., et al.: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral d-sotalol. *Lancet*, 1996, 348, s. 6–12.
- 9 Singh, S. – Berk, M. – Yellen, I. G. – Zable, R. G. – Abrahamson, D. – Satler, C. A.: Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: a multicenter study (Abstr). *Circulation*, 1997, 96 (dopl. 1), s. 383.
- 10 Dalrymple, H. – Campbell, T. – Channer, K. S. – Kingma, J. H. – Greenbaum, R. A. – Santini, M., et al.: Maintenance of sinus rhythm by dofetilide improves quality of life. The EMERALD (European and Australian Multicenter Evaluative Research on Atrial Fibrillation Dofetilide) study (Abstr). *Circulation*, 1998, 98 (dopl. 1), s. 13–14.
- 11 Craig, M. – Pratt, M. D. – Singh, S. N., et al.: The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction. Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. *J Am Coll Cardiol*, 2004, 43, s. 1211–1216.
- 12 Hodeige, D. – Heyndrickx, J. P. – Chatelain, P. – Manning, A.: SR 33589, a new amiodarone like antiarrhythmic agent: anti-adrenoceptor activity in anesthetized and conscious dogs. *Eur J Pharmacol*, 1995, 279, s. 25–32.
- 13 Kober, L. – Torp-Pedersen, C. – McMurray, J., et al.: Increased mortality after dronedarone therapy for severe heart failure. *N Engl J Med*, 2008, 358, s. 2678–2687.
- 14 Hohnloser, S. H. – Crijns, H. J. – Van Eickels, M., et al.: Effect of dronedarone on cardiovascular events in atrial fibrillation. *N Engl J Med*, 2009, 360, s. 668–678.
- 15 Le Heuzey, J. Y. – De Ferrari, G. M. – Radzik, D., et al.: A short term, randomized, double blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. *J Cardiovasc Electrophysiol*, 2010, 21, s. 597–605.
- 16 Connolly, S. J. – Camm, A. J. – Halperin, J. L., et al.: Dronedarone in High-Risk Permanent Atrial Fibrillation. *N Engl J Med*, 2011, 365, s. 2268–2276.
- 17 Chi, L. – Park, J. L. – Friedrichs, G. S. – Banglawala, Y. A. – Perez, M. A. – Tanheheo, E. J., et al.: Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. *Br J Pharmacol*, 1996, 117, s. 1261–1269.
- 18 Camm, A. J. – Capucci, A. – Hohnloser, S. H., et al.: A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodaron in recent-onset atrial fibrillation. *J Am Coll Cardiol*, 2011, 57, s. 313–321.

# Katetrizační ablace fibrilace síní: indikace, metody, výsledky

MUDr. Jan Petruš Antiarytmická jednotka, Kardiologické oddělení Nemocnice Na Homolce, Praha

- 1 Fiala, M.: Srdeční selhání (a nejen srdeční selhání) a fibrilace síní: rozevírající se nůžky mezi důkazy a praxí. *Cor Vasa*, 2009, 51(9), s. 584–589.
- 2 Natale, A. – Raviele, A.: *Atrial fibrillation ablation*. Update The State of the Art Based on the VeniceChart International Consensus Document, Blackwell Publishing, 2011.
- 3 Calkins, H., et al.: HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design. *Europace*, 2012.
- 4 Fuster, V., et al.: ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation. *Europace*, 2006, 8, s. 651–745.
- 5 Jalife, J. – Berenfeld, O. – Mansour, M.: Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation. *Cardiovasc Res*, 2002, 54(2), s. 204–216.
- 6 Shiroshita-Takeshita, A. – Brundel, B. J. – Nattel, S.: Atrial fibrillation: basic mechanisms, remodeling and triggers. *J Interv Card Electrophysiol*, 2005, 13(3), s. 181–193.
- 7 Allesie, M. – Ausma, J. – Schotten, U.: Electrical, contractile and structural remodeling during atrial fibrillation. *Cardiovasc Res*, 2002, 54(2), s. 230–246.
- 8 Katritsis, D. G. – Giazizoglou, E. – Zografos, T. – Pokushalov, E. – Po, S. S. – Camm, A. J.: Rapid pulmonary vein isolation combined with autonomic ganglia modification: a randomized study. *Heart Rhythm*, 2011, 8(5), s. 672–678.
- 9 Nakagawa, H. Y. K. – Scherlag, B. J. – Katari, V. – Aoyama, H. – Foresti, S. – Jackman, W. M.: Ablation of Autonomic Ganglia. In: Steinberg, J. S. C. H. – Jais, P., ed.: *A Practical Approach to Catheter Ablation of Atrial Fibrillation*. Lippincott, Williams a Wilkins Publishing, 2008, s. 218–230.
- 10 Nakagawa, H. S. B. – Patterson, E. – Ikeda, A. – Lockwood, D. – Jackman, W. M.: Pathophysiologic basis of autonomic ganglionated plexi ablation in patients with atrial fibrillation. *Heart Rhythm*, 2009, 6, s. S26–S34.
- 11 Po, S. S. – Nakagawa, H. – Jackman, W. M.: Localization of left atrial ganglionated plexi in patients with atrial fibrillation. *J Cardiovasc Electrophysiol*, 2009, 20(10), s. 1186–1189.
- 12 Haissaguerre, M. – Shah, D. C. – Jais, P., et al.: Electrophysiological breakthroughs from the left atrium to the pulmonary veins. *Circulation*, 2000, 102, s. 2463–2465.
- 13 Čihák, R., et al.: Doporučené postupy u pacientů s fibrilací síní. *Cor Vasa*, 2011, 53 (Suppl. 1).
- 14 Bhargava, M. – Di Biase, L. – Mohanty, P., et al.: Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: Result from a multicenter study. *Heart Rhythm*, 2009, 6, s. 1403–1412.
- 15 Oral, H. – Chugh, A. – Ozaydin, M., et al.: Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. *Circulation*, 2006, 114(8), s. 759–765.
- 16 Themistoclakis, S. – Corrado, A. – Marchlinski, F. E., et al.: The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. *J Am Coll Cardiol*, 2010, 55(8), s. 735–743.
- 17 Lambert, T. – Steinwender, C. – Leisch, F. – Hofmann, R.: Cardiac tamponade following pericarditis 18 days after catheter ablation. *Clin Res Cardiol*, 2010, 99, s. 595–597.
- 18 Pappone, C. – Augello, G. – Sala, S.: A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. The APAF study. *J Am Coll Cardiol*, 2006, 48, s. 2340–2347.
- 19 Link, M. S.: Ablation for Atrial Fibrillation: Not Risk Free. *Journal Watch*, 2009, 15(7).
- 20 Sıklódy, C. H., et al.: Incidence of Asymptomatic Intracranial Embolic Events After Pulmonary Vein Isolation. *JACC*, 2011, 7, s. 681–688.
- 21 Weerasooriya, R., et al.: Catheter ablation for atrial fibrillation: Are results maintained at 5 years of follow-up? *J Am Coll Cardiol*, 2011, 57, s. 160–166.
- 22 Oyang, F., et al.: Long-term results of catheter ablation in paroxysmal atrial fibrillation: Lessons from 5-year follow-up. *Circulation*, 2010, 122, s. 2368–2377.
- 23 Cappato, R. – Calkins, H. – Chen, S. A., et al.: Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circulation*, 2010, 3, s. 32–38.
- 24 Bertaglia, E., et al.: Does catheter ablation cure atrial fibrillation? Single-procedure outcome of drug-refractory atrial fibrillation ablation: A 6-year multicentre experience. *Europace*, 2010, 12, s. 181–187.

## Natriuretické peptidy a nové biomarkery chronického srdečního selhání

doc. MUDr. Filip Málek, Ph.D., MBA

Ambulance srdečního selhání, Kardiologické oddělení Nemocnice Na Homolce, Praha

- 1 Sudoh, T. – Kangawa, K. – Minamino, A., et al.: A new natriuretic peptide in porcine brain. *Nature*, 1988, 332, s. 78–81.
- 2 de Bold, A.: Heart atria granularity: effects of changes in water-electrolyte balance. *Proc Soc Exp Biol Med*, 1979, 161, s. 508–511.
- 3 Wilkins, M. R. – Redondo, J.: The natriuretic peptide-family. *Lancet*, 1997, 349, s. 1307–1310.
- 4 Bonow, R.: New Insights Into the Cardiac Natriuretic Peptides. *Circulation*, 1996, 93(11), s. 1946–1950.
- 5 Grantham, J. A. – Burnett, J. C.: BNP: Increasing Importance in the Pathophysiology and Diagnosis of Congestive Heart Failure. *Circulation*, 1997, 96(2), s. 388–390.
- 6 Levin, E. R. – Gardner, D. – Samson, W. K.: Natriuretic Peptides. *NEJM*, 1998, 339, s. 321–328.
- 7 Greenberg, R. N. – Hill, M. – Crytzer, J., et al.: Comparison of effects of uroguanylin, guanylin, and Escherichia coli heat-stable enterotoxin in mouse intestine and kidney: evidence that uroguanylin is an intestinal natriuretic hormone. *J Invest Med*, 1997, 45, s. 276–283.
- 8 Suga, S. – Nakao, K. – Hosoda, K. – et al.: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. *Endocrinology*, 1992, 130, s. 229–239.
- 9 Maack, T. – Suzuki, M. – Almeida, F. A., et al.: Physiological role of silent receptors of atrial natriuretic factor. *Science*, 1987, 238, s. 675–678.
- 10 Clavell, A. L. – Stingo, A. J. – Wei, C. M., et al.: C-type natriuretic peptide: a selective cardiovascular peptide. *Am J Physiol*, 1993, 264, s. R290–R295.

- 11 Furuya, M. – Yoshida, M. – Hayashi, A., et al.: C-type natriuretic peptide is a growth inhibitor of rat vascular smooth muscle cells. *Biochem Biophys Res Commun*, 1991, 177, s. 927–931.
- 12 Harris, P. J. – Thomas, D. – Morgan, T. O.: Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. *Nature*, 1987, 326, s. 697–698.
- 13 Dillingham, M. A. – Anderson, R. J.: Inhibition of vasopressin action by atrial natriuretic factor. *Science*, 1986, 231, s. 1572–1573.
- 14 Kim, J. K. – Sumner, S. N. – Dürr, J., et al.: Enzymatic and binding effects of atrial natriuretic factor in glomeruli and nephrons. *Kidney International*, 1989, 35, s. 799–805.
- 15 Steele, M. K. – Gardner, D. G. – Xie, P. L. – Schultz, H. D.: Interactions between ANP and ANG II in regulating blood pressure and sympathetic outflow. *Am J Physiol*, 1991, 260, s. R1145–R1151.
- 16 Morita, E. – Yasue, H. – Yoshimura, M., et al.: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. *Circulation*, 1993, 88, s. 82–91.
- 17 Omland, T. – Aakvaag, A. – Bonarjee, V. V. S., et al.: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. *Circulation*, 1996, 93, s. 1963–1969.
- 18 Arakawa, A. – Nakamura, M. – Aoki, H. – Hiramori, K.: Plasma brain natriuretic peptide concentrations predict survival after acute myocardial infarction. *J Am Coll Cardiol*, 1996, 27, s. 1656–1661.
- 19 Tsumamoto, T. – Wada, A. – Maeda, K., et al.: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. *Circulation*, 1997, 96, s. 509–516.
- 20 Grantham, J. A. – Borgeson, D. D. – Burnett, J. C. Jr.: Brain natriuretic peptide: pathophysiologic and potential therapeutic roles in acute heart failure. *Am J Physiol*, 1997, 272, s. R1077–1083.
- 21 Omland, T. – Bonarjee, V. V. S. – Lie, R. T.: Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. *Am J Cardiol*, 1995, 76, s. 230–235.
- 22 deLemos, J. A. – Morrow, D. A. – Bentley, J. H., et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. *New England Journal of Medicine*, 2001, 345 (14), s. 1014–1021.
- 23 Cheng, V. – Kazanegra, R. – Garcia, A., et al.: A Rapid Bedside Test for B-Type Peptide Predicts Treatment Outcomes in Patients Admitted for Decompensated Heart Failure: A Pilot Study. *Journal of the American College of Cardiology*, 2001, 37, s. 386–391.
- 24 Maeda, K. – Tsutamoto, T. – Wada, A., et al.: High Levels of Plasma Brain Natriuretic Peptide and Interleukin-6 After Optimized Treatment for Heart Failure Are Independent Risk Factors for Morbidity and Mortality in Patients With Congestive Heart Failure. *Journal of the American College of Cardiology*, 2000, 36, s. 1587–1593.
- 25 Murdoch, D. R. – McDonagh, T. A. – Byrne, J., et al.: Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. *American Heart Journal*, 1999, 138, s. 1126–1132.
- 26 Troughton, R. W. – Frampton, M. C. – Yandle, T. G., et al.: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide concentrations. *Lancet*, 2000, 355, s. 1126–1130.
- 27 Kubánek, M. – Málek, I. – Bytešník, J., et al.: Decrease in plasma B-type natriuretic peptide early after cardiac resynchronization therapy predicts clinical improvement at 12 months. *European Journal of Heart Failure*, 2006, 8, s. 832–840.
- 28 Pfisterer, M. – Buser, P. – Riskli, H., et al.: BNP-Guided vs Symptom-Guided Heart Failure Therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) Randomized Trial. *JAMA*, 2009, 301 (4), s. 383–392.
- 29 Shafiq, U. – Rehman, T. – Mueller, J. – Januzzi, L. Jr.: Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure. *Journal of the American College of Cardiology*, 2008, 52 (18), s. 1458–1465.
- 30 Braumwald, E.: Biomarkers in heart failure. *New England Journal of Medicine*, 2008, 358, s. 2148–2159.
- 31 Shimp, M. – Morrow, D. A. – Weinberg, E. O., et al.: Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. *Circulation*, 2004, 109, s. 2186–2190.
- 32 Weinberg, E. O. – Shimp, M. – Keulenaer, G. W., et al.: Expression and regulation of ST2, and interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. *Circulation*, 2002, 106, s. 2961–2966.
- 33 Mueller, T. – Dieplinger, B. – Gegenhuber, A., et al.: Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. *Clinical Chemistry*, 2008, 54, s. 752–756.
- 34 Weinberg, E. O. – Shimp, M. – Hurwitz, S., et al.: Identification of serum soluble ST2 receptor as a novel heart failure biomarker. *Circulation*, 2003, 107, s. 721–726.
- 35 Januzzi, J. L. Jr. – Peacock, W. F. – Maisel, A. S., et al.: Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE study. *Journal of the American College of Cardiology*, 2007, 50, s. 607–613.
- 36 Pascual-Figal, D. A. – Ordonez-Llanos, J. – Tornel, P. L., et al. for MUSIC Investigators: Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. *Journal of the American College of Cardiology*, 2009, 54, s. 2174–2179.
- 37 Ky, B. – French, B. – McCloskey, K., et al.: High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. *Circulation: Heart Failure*, 2011, 4, s. 180–187.
- 38 Genis-Bayes, A. – deAntonio, M. – Galán, A., et al.: Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. *European Journal of Heart Failure*, 2012, 14, s. 32–38.
- 39 Kimmenade, R. R. – Januzzi, J. L. – Ellinor, P. T., et al.: Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients With Acute Heart Failure. *Journal of the American College of Cardiology*, 2006, 48 (6), s. 1217–1224.
- 40 de Boer, R. A. – Voors, A. A. – Muntendam, P., et al.: Galectin-3: a novel mediator of heart failure development and progression. *European Journal of Heart Failure*, 2009, 11, s. 811–817.
- 41 Lopez-Andres, N. – Rossignol, P. – Iraqui, W., et al.: Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from CARE-HF trial. *European Journal of Heart Failure*, 2012, 14, s. 74–81.
- 42 Yamaha, B. – Nagaya, N.: Adrenomedullin: molecular mechanisms and its role in cardiac disease. *Amino Acids*, 2007, 32, s. 157–164.
- 43 Richards, A. M. – Doughty, R. – Nicholls, N. G., et al.: Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. *Journal of the American College of Cardiology*, 2001, 37, s. 1781–1787.
- 44 Pousset, F. – Mason, F. – Chavirovskaia, O., et al.: Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. *European Heart Journal*, 2000, 21, s. 1009–1014.
- 45 Morgenthaler, N. G. – Struck, J. – Jochberger, S. – Dünser, M.: Copeptin: clinical use of a new biomarker. *Trends in Endocrinology and Metabolism*, 2007, 19 (2), s. 43–49.
- 46 Katan, M. – Miller, B. – Christ-Crain, M.: Copeptin: a new and promising diagnostic and prognostic marker. *Critical Care*, 2008, 12 (2), s. 117.
- 47 Khan, S. Q. – Dhillon, O. S. – O'Brien, R. J., et al.: C-Terminal Provasopressin (Copeptin) as a Novel and Prognostic Marker in Acute Myocardial Infarction. *Circulation*, 2007, 115, s. 1–8.
- 48 Neuhold, S. – Huelsman, M. – Strunk, G., et al.: Comparison of Copeptin, B-Type Natriuretic Peptide, and Amino-Terminal Pro-B-Type Natriuretic Peptide in Patients With Chronic Heart Failure: Prediction of Death at Different Stages of the Disease. *Journal of the American College of Cardiology*, 2008, 52, s. 266–272.

# Srdeční amyloidóza – od historie k moderní diagnostice

doc. MUDr. Eva Mandysová, CSc. | doc. MUDr. Petr Neužil, CSc., FESC

Kardiologické oddělení Nemocnice na Homolce, Praha

- 1 Kyle, R. A.: Historical review. Amyloidosis a convoluted story. *Br J Haematol*, 2001, 114, s. 529–538.
- 2 Pepys, M. B.: Amyloidosis. *Annu Rev Med*, 2006, 57, s. 223–241.
- 3 Liu, D. – Niemann, M. – Hu, K., et al.: Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. *Am J Cardiol*, 2011, 108, s. 591–598.
- 4 Falk, R. H. – Plehn, J. F. – Deering, T., et al.: Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. *Am J Cardiol*, 1987, 59, s. 418–422.
- 5 Kyle, R. A. – Gertz, M. A.: Primary systemic amyloidosis: clinical and laboratory features in 474 cases. *Semin Hematol*, 1995, 32, s. 45–59.
- 6 Klein, A. L. – Hatle, L. K. – Burstow, D. J., et al.: Doppler characterization of left ventricular diastolic function in cardiac amyloidosis. *J Am Coll Cardiol*, 1989, 13, s. 1017–1026.
- 7 Palka, P. – Lange, A. – Donnelly, J. E., et al.: Doppler tissue echocardiographic features of cardiac amyloidosis. *J Am Soc Echocardiogr*, 2002, 15, s. 1353–1360.
- 8 Koyama, J. – Davidoff, R. – Falk, R. H.: Longitudinal myocardial velocity gradient derived from pulsed Doppler tissue imaging in AL amyloidosis: a sensitive indicator of systolic and diastolic dysfunction. *J Am Soc Echocardiogr*, 2004, 17, s. 36–44.
- 9 Liu, D. – Niemann, M. – Hu, K., et al.: Echocardiographic Evaluation of Systolic and Diastolic Function in Patients With Cardiac Amyloidosis. *Am J Cardiol*, 2011, 108, s. 591–598.
- 10 Bellavia, D. – Pellikka, P. A. – Al-Zahrani, G. B., et al.: Independent predictors of survival in primary systemic (AL) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. *J Am Soc Echocardiogr*, 2010, 23, s. 643–652.
- 11 Bellavia, D. – Abraham, T. P. – Pellikka, P. A., et al.: Detection of the left ventricular systolic dysfunction in cardiac amyloidosis with strain rate echocardiography. *J Am Soc Echocardiogr*, 2007, 20, s. 1194–1202.
- 12 Sun, J. P. – Stewart, W. J. – Yang, X. S., et al.: Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. *Am J Cardiol*, 2009, 103, s. 411–415.
- 13 Kusunose, K. – Yamada, H. – Nishi, S., et al.: Detection of myocardial amyloid involvement using 2-dimensional speckle tracking echocardiography: utilization of inner and outer myocardial strain and strain rate. *JACC*, 2010, 55, s. 10A.
- 14 Park, S. J. – Miyazaki, C. – Bruce, C. J. – Ommen, S. – Miller, F. A. – Oh, J. K.: Left ventricular torsion by two-dimensional speckle tracking echocardiography in patients with diastolic dysfunction and normal ejection fraction. *J Am Soc Echocardiogr*, 2008, 21, s. 1129–1137.
- 15 Cappelli, F. – Porciani, M. C. – Bergesio, F., et al.: Right ventricular function in AL amyloidosis: characteristics and prognostic implication. *Eur J Echocardiogr*, doi:10.1093/ejehocardi/jer289.
- 16 Mohty, D. – Pibarot, P. – Dumesnil, J. G., et al.: Left atrial size is an independent predictor of overall survival in patients with primary systemic amyloidosis. *Archives of Cardiovascular Disease*, 2011, 104, s. 611–618.
- 17 Fitzgerald, B. T. – Scalia, G. M. – Cain, P. A.: Left atrial size—Another Differentiator for Cardiac Amyloidosis. *Heart, Lung and Circulation*, 2011, 20, s. 574–578.
- 18 Perugini, E. – Rapezzi, C. – Piva, T., et al.: Non-invasive evaluation of myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. *Heart*, 2006, 92, s. 343–349.
- 19 Kapoor, P. – Thenappan, T. – Singh, E., et al.: Cardiac amyloidosis: a practical approach to diagnosis and management. *Am J Med*, 2011, 124, s. 1006–1015.
- 20 Meier-Ewert, H. K. – Sanchorawala, V. – Berk, J. L., et al.: Cardiac amyloidosis: evolving approach to diagnosis and management. *Curr Treat Options Cardiovasc Med*, 2011, 13, s. 528–542.

## Očkování proti pertusi

MUDr. Kateřina Fabiánová Státní zdravotní ústav,

Centrum epidemiologie a mikrobiologie, Oddělení epidemiologie infekčních nemocí,

3. lékařská fakulta Univerzity Karlovy, Ústav epidemiologie

- 1 Mattoo, S. – Cherry, J. D.: Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies. *Clin Microbiol Rev*, 2005, 18 (2), s. 326–382.
- 2 Cherry, J. D.: Pertussis in adults. *Ann Intern Med*, 1998, 128 (1), s. 64–66.
- 3 Cherry, J. D.: Historical review of pertussis and the classical vaccine. *J Infect Dis*, 1996, 174 (dopl. 3), s. 259–263.
- 4 Poolman, J. T. – Hallander, H. – Halperin, S. A.: Pertussis vaccines: where to now? *Expert Rev Vaccines*, 2011, 10 (11), s. 1497–1500.
- 5 Edwards, K. M. – Decker, M. D.: Pertussis vaccine. In: Plotkin, S. A. – Orenstein, W. A.: Vaccines. Saunders, Philadelphia, 2004, s. 471–521.
- 6 Crowcroft, N. S. – Pebody, R. G.: Recent developments in pertussis. *Lancet*, 2006, 367 (9526), s. 1926–1936.
- 7 Bisgard, K. M. – Pascal, F. B. – Ehresmann, K. R., et al.: Infant pertussis: who was the source? *Pediatr Infect Dis J*, 2004, 23 (11), s. 985–989.
- 8 Wendelboe, A. M. – Njamkepo, E. – Bourillon, A., et al.: Transmission of Bordetella pertussis to young infants. *Pediatr Infect Dis J*, 2007, 26 (4), s. 293–299.
- 9 Castagnini, L. A. – Healy, C. M. – Rench, M., et al.: Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. *Clin Infect Dis*, 2012, 54 (1), s. 78–84.



# Pohled ambulantního lékaře na očkování proti HPV

MUDr. Jiří Dvořák člen HPV College, Gynekologická ambulance, Kolín

- 1 Bosch, F. X. – Castellsague, X. – Sanjosé, S.: HPV and cervical cancer: screening or vaccination. *Br J of Cancer*, 2008, 98, s. 15–21.
- 2 Crosbie, E. J. – Kitchener, H. C.: Cervarix – a bivalent L1 VLP vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancer. *Expert Opin Biol Ther*, 2007, 7, 3, s. 391–395.
- 3 de Villiers, E. M. – Fauquet, C. – Broker, T. R., et al.: Classification of papillomaviruses. *Virology*, 2004, 324, s. 17–27.
- 4 Fraser, C. – Tomassini, J. E. – Xi, L., et al.: Modeling the long-term antibody response of HPV VLP type 16 prophylactic vaccine. *Vaccine*, 2007, 25, s. 4324–4333.
- 5 **FUTURE II Study Group**: Quadrivalent Vaccine against HPV to prevent high-grade cervical lesions. *NEJM*, 2007, 356, 19, s. 1915–1927.
- 6 Garland, S. M. – Hernandez-Avila, M. – Wheeler, C. M., et al.: Quadrivalent vaccine against HPV to prevent anogenital disease (FUTURE I). *N Engl J Med*, 2007, 356, 19, s. 1928–1943.
- 7 Giannini, S. L. – Hanon, E. – Moris, P., et al.: Enhanced humoral and memory B cellular immunity using HPV 16/18 LV VLP vaccine formulated with the MLP/aluminium salt combination (AS04) compared to aluminium salt only. *Vaccine*, 2006, 24, s. 5937–5949.
- 8 Harper, M. – Paavonen, J.: Age for HPV vaccination. *Vaccine*, 2008, 26, s. A7–11.
- 9 Jaura, E. A. – Leodolter, S. – Hernandez-Avila, M., et al.: Efficacy of quadrivalent prophylactic HPV (type 6, 11, 16, 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. *Lancet*, 2007, 369, s. 1693–1702.
- 10 Markowitz, L. E. – Dune, E. F. – Saraiya, M., et al.: Quadrivalent human papillomavirus vaccine. *MMWR*, 12. 3. 2007, 56, s. 1–20.
- 11 Muñoz, N. – Manalastas, R. – Pitisuttithum, P., et al.: Safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. *Lancet*, 2009, 373, s. 1949–1957.
- 12 Paavonen, J. – Jenkins, D. – Bosh, F. X., et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like particle vaccine against infection with human papillomavirus types 16 and 18 in young women. *Lancet*, 2007, 369, s. 2161–2170.
- 13 Villa, L. L. – Ault, K. A. – Giulian, A. R.: Immunologic response following administration of a vaccine targeting HPV types 6, 11, 16 a 18. *Vaccine*, 2006, 7, s. 557–583.
- 14 White, W. I. – Wilson, S. D. – Bonnez, W., et al.: In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. *J Virol*, 1998, 72, s. 959–964.
- 15 Winer, R. L. – Lee, S.-K. – Hughes, J. P., et al.: Genital HPV infection: Incidence and risk factors in a cohort of female university students. *Am J Epidemiol*, 2003, 157, s. 218–226.
- 16 Mouková, L. – Feranec, R. – Chovanec, J.: Vakcinace proti lidskému papillomaviru v ČR. *Klin Onkol*, 2010, 23 (2), s. 125–126.
- 17 Chovanec, J.: Oddělení gynekologické onkologie, Masarykův onkologický ústav, Brno. *Klin Onkol*, 2010, 23 (2), s. 125–126.
- 18 Petráš, M. – Lesná, I. K.: *Manuál očkování 2010*. Marek Petráš, 2010.
- 19 Fait, T.: Současný přístup k očkování proti HPV. *Pediatric pro praxi*, 2009, 1, s. 31–34.

## Inkretiny a jejich místo v terapii diabetu

MUDr. Mgr. Sylvie Špitálníková, Ph.D. | MUDr. Jiří Hradec Diabetologická ambulance, Chrudim

- 1 Ústav zdravotnických informací a statistiky České republiky: *Aktuální informace o činnosti oboru diabetologie, péči o diabetiky v roce 2010*. Aktuální informace č. 26/2011.
- 2 Nauck, M. A., et al.: Reductet incretin effect in Type 2 (non-insulin-dependent) diabetes. *Diabetologia*, 1986, 29, s. 46–52.
- 3 Kim, W. – Egan, J. M.: The role of incretins in glucose homeostasis and diabetes treatment. *Pharmacol Rev*, 2008, 60, s. 470–512.
- 4 Rybka, J. – Kvapil, M.: Inkretinová léčba diabetu. *Post.med.*, 2011, 4, s. 441–450.
- 5 Bunck, M. C. – Diamant, M. – Corner, A., et al.: One-year treatment with exenatide improves beta-cell function compared to insulin glargine, in metformin treated type 2 diabetes patients: a randomized, controlled trial. *Diabetes Care*, 2009, 32, s. 762–768.
- 6 Bergenstal, R. – Lewin, A. – Bailey, T. – Chang, D. – Gylvin, T. – Roberts, V.: Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. *Curr Med Res Opin*, 2009, 25, s. 65–75.
- 7 Davis, S. N., et al.: Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agent. *Diabetes Care*, 2007, 30, s. 2972–2973.
- 8 Kim, D., et al.: Effects of once-weekly dosing of a long-acting release formulation of exenatid on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care*, 2007, 30, s. 1487–1493.
- 9 Christensen, M., et al.: Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. *Drugs*, 2009, 12, s. 503–513.
- 10 Mari, A., et al.: Effects of the long acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. *Diabetes Care*, 2007, 30, s. 2032–2033.
- 11 Buse, J. B., et al.: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). *Lancet*, 2009, 4, 374, s. 39–47.
- 12 Horowitz, M., et al.: Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. *Diabetes Obes Metab*, 2008, 10, s. 593–596.
- 13 Kvapil, M. – Anděl, M.: *Terapeutické využití inkretinů*. Doporučení české diabetologické společnosti, 2008.
- 14 Sullivan, S. D., et al.: Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. *Cardiovasc Diabetol*, 2009, 26, 8, s. 12.
- 15 Tomkin, G. H.: Albiglutide, an albumin-based fusion of glucagon-like peptide 1 for potential treatment of type 2 diabetes. *Curr Opin Mol Ther*, 2009, 11, s. 579–588.
- 16 *Onglyza. Summary of product characteristics*. Bristol Myers Squibb/AstraZeneca, EEIG, 2011.
- 17 *Januvia. Summary of product characteristics*. Merck Sharp and Dohme, Ltd., 2011.
- 18 *Galvus. Summary of product characteristics*. Novartis Europharm, Ltd., 2011.
- 19 *Trajenta. Summary of product characteristics*. Boehringer Ingelheim International, GmbH, 2011.
- 20 *Souhrn údajů o přípravku liraglutid*. Revize leden 2010.
- 21 *Souhrn údajů o přípravku Byetta*. 2008.

- 22 Goldstein, B. J., et al.: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. *Diabetes Care*, 2007, 30, s. 1979–1987.
- 23 Dejager, S., et al.: Vildagliptin in drug-naive patients with Type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. *Horm. Metab. Res.*, 2007, 39, s. 218–223.
- 24 DeFronzo, R. A. – Hissa, M. N. – Garber, A. J. – Gross, J. L. – Duan, R. Y. – Ravichandran, S. – Chen, R. S., et al.: The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone. *Diabetes Care*, 2009, 32, 9, s. 1649–1655.
- 25 Taskinen, M. R. – Rosenstock, J. – Tamminen, I. – Kubiak, R. – Patel, S. – Dugi, K. A. – Woerle, H. J.: Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Diabetes Obes Metab*, 2011, 13 (1), s. 65–74.

## Imunologické a epidemiologické aspekty pneumokokového očkování

RNDr. Marek Petráš InterImun, s. r. o., Pardubice

- 1 Macleod, C. M. – Hodges, R. G. – Heidelberger, M. – Bernhard, W. G.: Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. *J Exp Med*, 1945, 82 (6), s. 445–465.
- 2 Taylor, S. – Marchisio, P. – Vergison, A. – Harriague, J. – Hausdorff, W. P. – Haggard, M.: Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. *Clin Infect Dis*, 2012.
- 3 Fernandez, J. – Levine, O. S. – Sanchez, J. – Balter, S. – LaClaire, L. – Feris, J. – Romero-Steiner, S.: Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. *J Infect Dis*, 2000, 182 (5), s. 1553–1556.
- 4 Skinner, J. M. – Indrawati, L. – Cannon, J. – Blue, J. – Winters, M. – Macnair, J. – Pujar, N. – Manger, W. – Zhang, Y. – Antonello, J. – Shiver, J. – Caulfield, M. – Heinrichs, J. H.: Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model. *Vaccine*, 2011, 29 (48), s. 8870–8876.
- 5 Black, S. – Shinefield, H. – Fireman, B. – Lewis, E. – Ray, P. – Hansen, J. R. – Elvin, L. – Ensor, K. M. – Hackell, J. – Siber, G. – Malinoski, F. – Madore, D. – Chang, I. – Kohberger, R. – Watson, W. – Austrian, R. – Edwards, K.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. *Pediatr Infect Dis J*, 2000, 19 (3), s. 187–195.

## Najde přenos buněčných jader uplatnění v medicíně?

prof. Ing. Jaroslav Petr, DrSc. Výzkumný ústav živočišné výroby, Praha

- 1 Solano, A. – Playan, A. – Lopez-Perez, M. J., Montoya, J.: Genetic diseases of the mitochondrial DNA in humans. *Salud publica se Mexico*, 2001, 43, s. 151–161.
- 2 Lin, M. T. – Beal, M. F.: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. *Nature*, 2006, 443, s. 787–795.
- 3 Šutovský, P. – Moreno, R. M., Ramalho-Santos, J. – Dominko, T. – Simerly, C. – Schatten, G.: Ubiquitin tag for sperm mitochondria. *Nature*, 1999, 402, s. 371–372.
- 4 Taylor, R. W. – Turnbull, D. M.: Mitochondrial DNA mutations in human disease. *Nature Reviews Genetics*, 2005, 6, s. 389–402.
- 5 Steffann, J. – Frydman, N. – Gigarel, N. – Burlet, P. – Ray, P. F., Fanchin, R. – Feyreisen, E. – Kerbrat, V. – Tachdjian, G. – Bonnefont, J. P. – Frydman, R. – Munnich, A.: Analysis of mtDNA variant segregation during early human embryonic development: tool for successful NARP preimplantation diagnosis. *Journal of Medical Genetics*, 2006, 43, s. 244–247.
- 6 Brown, D. T. – Herbert, M. – Lamb, V. K. – Chinnery, P. F. – Lightowlers, R. N. – Craven, L. – Cree, L. – Gardner, J. L. – Turnbull, D. M.: Transmission of mitochondrial DNA disorders: possibilities for the future. *Lancet*, 2006, 368, s. 87–89.
- 7 Tachibana, M. – Sparman, M. – Sritanaudomcha, H. – Ma, H. – Clepper, L. – Woodward, J. – Li, Y. – Ramsey, C. – Kolotushkina, O. – Mitalipov, S.: Mitochondrial gene replacement in primate offspring and embryonic stem cells. *Nature*, 2009, 461, s. 367–372.
- 8 Craven, L. – Tuppen, H. A. – Greggains, G. D. – Harbottle, S. J. – Murphy, J. L. – Cree, L. M. – Murdoch, A. P. – Chinnery, P. F. – Taylor, R. W., Lightowlers, R. N. – Herbert, M. – Turnbull, D. M.: Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. *Nature*, 2010, 465, s. 82–85.
- 9 Anonymous: Fertile union. *Nature*, 2012, 481, s. 410.
- 10 Callaway, E.: UK sets sight on gene therapy in eggs. *Nature*, 2012, 481, s. 419.